Posted with link, abstract, highlights, and intro in off-topic forum and over on Zenith board

But 

In a study of BETinhibition in pediatric cancers. Some major players joined in, but Zenith didn't even respond. See last line.

• There were 47 participants: 15 academic experts; 20 representatives from eight companies with publicly recognised BET inhibitor development plans (BMS/Celgene, Boehringer Ingelheim, Constellation Pharmaceuticals, AstraZeneca, Incyte, Plexxikon, Developmental Therapeutics Consortium and Abbvie); four patient advocates (Andrew McDonough B+ Positive Foundation, Children's Cancer Cause, Coalition Against Childhood Cancer, Solving Kids' Cancer); six regulators from the FDA and EMA as observers; and two organisers. GlaxoSmithKline was initially intending to participate, but their product (molibresib) has been discontinued. Zenith Epigenetics did not respond to invitations.

Was this just a function of being stretched too thin already, or???

Wondering why.

Was this discussed already somewhere?